Open Access Open Access  Restricted Access Subscription Access

A Comparative Study of a Curcumin, Mesalazine and a Cox-2 Inhibitors as a Therapeutic Agents for Ulcerative Colitis by Using A Swiss-Dock Model

Vipul Dubey, Subba Dil

Abstract


Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by immune activation, leading to persistent inflammation and tissue damage in the colon. The Janus kinase 1 (COX2) pathway plays a pivotal role in cytokine-mediated immune responses, making it a crucial therapeutic target for UC management.. This study investigates the potential of a Curcumin-Mesalazine combination as a COX2 inhibitor using SwissDock molecular docking simulations. Curcumin, a natural polyphenol derived from Curcuma longa, possesses anti-inflammatory, antioxidant, and immunomodulatory properties, while Mesalazine (%-amminosalicylic acid) is a widely used UC treatment known for its mucosal healing effects. Through docking studies, we aim to evaluate their binding affinity and interaction with COX2, assessing their potential as natural therapeutic agents. Preliminary docking results indicate strong affinities, suggesting that Curcumin-Mesalazine combination could synergistically inhibit COX2 activity. This research provides a foundation for further in vitro and in vivo studies, supporting the development of alternatives for UC treatment with potentially fewer side effects.


Full Text:

PDF

References


Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012 Nov 3;380(9853):1606–19.

Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Mar 1;23(5):577–85.

Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Jun;4(6):760–5.

Arts J, D’Haens G, Zeegers M, Van Assche G, Hiele M, D’Hoore A, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004 Mar;10(2):73–8.

Hu X, Li J, Fu M, Zhao X, Wang W. The COX2/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther. 2021 Nov 26;6(1):1–33.

Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D. COX2-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed. 2023 Nov 8;4:40.

D’Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631.

Tung BT, Nham DT, Hai NT, Thu DK. Curcuma longa, the Polyphenolic Curcumin Compound and Pharmacological Effects on Liver. In: Watson RR, Preedy VR, editors. Dietary Interventions in Liver Disease [Internet]. Academic Press; 2019 [cited 2025 Mar 27]. p. 125–34. Available from: https://www.sciencedirect.com/science/article/pii/B9780128144664000100

Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z, et al. Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. Drug Des Devel Ther. 2021 Nov 2;15:4503–25.

Sohn SI, Priya A, Balasubramaniam B, Muthuramalingam P, Sivasankar C, Selvaraj A, et al. Biomedical Applications and Bioavailability of Curcumin—An Updated Overview. Pharmaceutics. 2021 Dec 7;13(12):2102.


Refbacks

  • There are currently no refbacks.